Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 14/F/822 | Other Grant/Funding Number | Department of Agriculture and Marine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine the effect of leucine-enriched protein supplementation, alone and in combination with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFA), on muscle mass and function in older adults at risk of sarcopenia.
The investigators hypothesize that LC n-3 PUFA supplementation will further enhance the efficacy of the leucine-enriched protein.
The progressive loss of skeletal muscle mass and function with advancing age, termed sarcopenia, contributes substantially to disability, physical dependence, and mortality among older adults. Aging is associated with an attenuated muscle protein synthetic response to the ingestion of small to moderate protein doses compared to younger persons. Several studies have reported that the acute, postprandial muscle protein synthesis (MPS) response to a suboptimal protein dose is enhanced when the leucine content of the protein bolus is increased. This indicates that supplementing the lower-protein daily meals (i.e., breakfast and lunch) with leucine may represent a practical strategy to augment the MPS response to these meals and, subsequently, attenuate sarcopenic muscle mass loss over time. In addition, LC n-3 PUFA supplementation has been shown to enhance the MPS response to amino acid infusion older adults suggesting that combined leucine and LC n-3 PUFA supplementation be particularly effective for improving daily MPS, muscle mass and function in older adults.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Protein-free, LC n-3 PUFA-free juice based supplement |
|
| Leucine-enriched protein | Experimental | Juice based supplement containing leucine-enriched protein |
|
| Leucine-enriched protein + LC n-3 PUFA | Experimental | Juice based supplement containing leucine-enriched protein and LC n-3 PUFA |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Dietary Supplement | Protein-free, LC n-3 PUFA-free juice based supplement |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Appendicular skeletal muscle mass | Assessed via dual energy x-ray absorptiometry | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Isometric knee extension strength | Maximal voluntary contraction | 6 months |
| Physical performance | Short physical performance battery, single leg stand, timed up and go |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Helen Roche, PhD | University College Dublin | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University College Dublin | Dublin | Ireland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33871558 | Derived | Murphy CH, Flanagan EM, De Vito G, Susta D, Mitchelson KAJ, de Marco Castro E, Senden JMG, Goessens JPB, Miklosz A, Chabowski A, Segurado R, Corish CA, McCarthy SN, Egan B, van Loon LJC, Roche HM. Does supplementation with leucine-enriched protein alone and in combination with fish-oil-derived n-3 PUFA affect muscle mass, strength, physical performance, and muscle protein synthesis in well-nourished older adults? A randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2021 Jun 1;113(6):1411-1427. doi: 10.1093/ajcn/nqaa449. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C485657 | P3H1 protein, human |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Leucine-enriched protein |
| Dietary Supplement |
Leucine-enriched whey protein |
|
| LC n-3 PUFA | Dietary Supplement | LC n-3 PUFA |
|
| 6 months |
| Metabolomics | Assessed using nuclear magnetic resonance (NMR) spectroscopy | 6 months |
| Transcriptomics | Assessed via RNA Sequencing | 6 months |
| Thigh muscle mass | Assessed in dominant leg via MRI in sub cohort (n=39) | 6 months |
| Muscle protein synthesis | Measured as fractional synthetic rate (%/day) over a 3-d period at baseline and end of study | 6 months |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |